| Identification | Back Directory | [Name]
IVHD-valtrate | [CAS]
28325-56-6 | [Synonyms]
Valtrate HD
IVHD-valtrate
Isovaleroxyhydroxydidrovaltratum
Isovaleroxyhydroxydihydrovaltrate
Butanoic acid, 3-methyl-2-(3-methyl-1-oxobutoxy)-, [(1S,2'R,4aR,6S,7aS)-6-(acetyloxy)-4a,5,6,7a-tetrahydro-4a-hydroxy-1-(3-methyl-1-oxobutoxy)spiro[cyclopenta[c]pyran-7(1H),2'-oxiran]-4-yl]methyl ester | [Molecular Formula]
C27H40O11 | [MDL Number]
MFCD28100656 | [MOL File]
28325-56-6.mol | [Molecular Weight]
540.6 |
| Hazard Information | Back Directory | [Uses]
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research[1]. | [Biological Activity]
IVHD-valtrate is an active Valeriana jatamansi derivative that inhibits human ovarian cancer cells in vitro and in vivo. It induces apoptosis of cancer cells and inhibits ovarian cancer cells from arresting in G2/M phase. It has the potential to be a new chemotherapeutic agent for human ovarian cancer research. | [in vitro]
IVHD-valtrate inhibits the growth and proliferation of the A2780 and OVCAR-3 ovarian cancer cell lines in a concentration-dependent manner. IVHD-valtrate results in a relatively low cytotoxicity to immortalized non-tumorigenic human ovarian surface epithelial cells (IOSE-144). | [target]
| [References]
[1] Xiaoguang Li, et al. Valeriana jatamansi constituent IVHD-valtrate as a novel therapeutic agent to human ovarian cancer: in vitro and in vivo activities and mechanisms. Curr Cancer Drug Targets. 2013 May;13(4):472-83. DOI:10.2174/1568009611313040009 |
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
|